EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2)

European Society for Blood and Marrow Transplantation60 enrolled

Overview

The aim of the study is to assess the effectiveness of various post-transplant treatment management approaches on clinical and immune biological responses after Autologous Hematopoietic Stem Cell transplantation (AHSCT) for Systemic Sclerosis (SSc) as currently performed by the different treatment protocols used in routine clinical practice across Europe in various EBMT centres

NISSc-2 is a prospective observational study specifically designed to assess the effectiveness of various post-transplant treatment management approaches on clinical and immune biological responses after Autologous Hematopoietic Stem Cell transplantation (AHSCT) for Systemic Sclerosis (SSc) as currently performed by the different treatment protocols used in routine clinical practice across Europe in various EBMT centres through the careful recording and analysis of routinely collected clinical and immune biological data, and specific data regarding post-transplant use of SSc active treatments, including: * Steroids, * SSc active treatments after AHSCT such as mycophenolate mofetil (MMF), azathioprine, cyclophosphamide (oral or IV), methotrexate, polyclonal antibodies (such as ATG) or monoclonal antibodies (rituximab, belimumab or any others) as well as their respective dosage and duration of each treatment. These post-transplant treatments can be administered for various reasons, which can be specified by local investigators, such as per local protocol decision for maintenance therapy, or for disease progression with or without prior clinical response, during routine clinical follow-up. Patients who do not receive any post-transplant therapy will also be observed. Different protocols are used in the different centres, but it is not yet clear, which approach will be the most efficient and the safest. The role of stem cell purification with CD34-selection also needs to be determined prospectively. In addition, the EBMT Autoimmune Diseases and Immunobiology Working Parties developed and implemented guidelines for 'good laboratory practice' in relation to procurement, processing, storage and analysis of biological specimens for immune reconstitution studies in AD patients before, during and after AHSCT \[16\]. To follow post-transplant immune reconstitution according to ADWP GCP, results of routine analyses performed by centres under standardized conditions on available biological samples will be investigated in correlation to clinical outcome parameters. Every centre will follow its own local protocol for AHSCT, which usually refers to the recent update of the EBMT guidelines for AHSCT in autoimmune disease. We therefore specifically designed NISCC-II to prospectively capture various post-ASHCT management protocols and their effect on the observed clinical response after AHSCT.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Autoimmune Diseases

Interventions

Autologous HSCTPROCEDURE

1st AHSCT

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. \- Autologous HSCT 2. \- Age above 18 years at time of transplant. 3. -. Established diagnosis of progressive SSc according to 2013 ACR/EULAR classification criteria Exclusion Criteria: 1. Pregnancy or inadequate contraception 2. Severe concomitant disease 3. Reduced lung, cardiac or renal function a. .Reduced lung function with FVC \< 50% or DLCO \< 30% (of predicted values) b; .Pulmonary arterial hypertension with baseline (resting) PASP \> 40 mmHg or mPAP \> 25 mmHg or a PASP \> 45 mmHg or mPAP \> 30 mmHg after fluid challenge or Pulmonary vascular resistance \> 3 Wood units on RHC c. Severe heart failure with Ejection Fraction \< 45% by cardiac echocardiography d. D-sign of septal bounce on cardiac MRI e. Unrevascularized severe coronary artery disease f. Untreated severe arrhythmia g. Cardiac tamponade h. Constrictive pericarditis i. Kidney insufficiency: creatinine clearance \<30ml/min Previously damaged bone marrow 1. Leukopenia \< 2.0 x 109/L (total white cell count) 2. Thrombocytopenia \< 100 x 109/L 4. Uncontrolled severe or chronic infection (Hepatitis B/C, HIV, Salmonella carrier, syphilis, tuberculosis) 5. Severe concomitant psychiatric illness (depression, psychosis) 6. Concurrent neoplasms or myelodysplasia in the past 5 years 7. Smoking (current)

Locations (1)

Badoglio Manuela- EBMT Paris Office

Paris, France

RECRUITING

Outcomes

Primary Outcomes

Progression free survival (PFS),

defined as survival since AHSCT without evidence of progression of SSc.

Time frame: 2 years post transplant

Secondary Outcomes

Treatment related toxicity

Treatment related toxicity throughout the study period using WHO toxicity parameters (expressed as maximum grade toxicity per organ system, see appendix) Incidence of Adverse Events (AE) and Serious Adverse Events (SE) Neutrophil and platelet engraftment, defined as first day after transplantation with absolute neutrophil count \> 0.5 x 109/L and platelet count \>20 x 109/L (without platelet transfusion).

Time frame: 100 days post-transplant

100 days Treatment Related Mortality (100d TRM)

defined as any death during 100 days following transplant that cannot be attributed to progression or relapse of the disease

Time frame: 100 days post-transplant

Overall Survival (OS)

Overall survival

Time frame: 2 years post-transplant

Use of prednisone equivalent

Use of prednisolone equivalent \> 6 mg/day for more than 3 months

Time frame: 1 year and 2 years post-transplant

Use of immunosuppressive drugs

defined as use of any post-transplant immunosuppressive drugs (mycophenolate mofetil, azathioprine, oral or iv cyclosphosphamide or methotrexate) for either causes (maintenance therapy as per local protocol decision, SSc progression or relapse) and total duration of exposure to this post-transplant immunosuppressive treatment (average monthly daily dose and months duration)

Time frame: 2 years post-transplant

Central Contacts

Manuela Badoglio, MS

CONTACT

+33 1 70 64 24 16 manuela.badoglio@upmc.fr

Dominique Farge, PhD

CONTACT

dominique.farge-bancel@aphp.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.